Opinion

Video

Treatment Resistance with Covalent BTKis: Translating Data into Clinical Practice

Author(s):

Catherine C. Coombs, MD,Brian T. Hill, MD, PhD

Javier Pinilla, MD, PhD explores evidence on molecular mechanisms leading to resistance in second-generation BTK inhibitors for CLL, providing insights from recently presented data at ASH 2023.

Related Videos
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Richard Kim, MD, Moffitt Cancer Center
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Tiago Biachi, MD, PhD
Related Content
FDA
November 20th 2024

FDA Approves New Drug Labeling for Fludarabine Phosphate in CLL

Aaron T. Gerds, MD, MS, assistant professor, Department of Medicine, School of Medicine, member, Developmental Therapeutics Program, Case Comprehensive Cancer Center, physician,Department of Hematology and Medical Oncology, Cleveland Clinic; James K. McCloskey, MD, interim chief, Division of Leukemia, Hackensack John Theurer Cancer Center
October 14th 2024

Navigating Myelofibrosis: Updates for Community Hematologist Oncologists

First-Line Zanubrutinib in CLL/SLL
November 13th 2024

First-Line Zanubrutinib Prolongs PFS in Real-World Study of Chinese Patients With CLL/SLL

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Matthew Cortese, MD, MPH, assistant professor, oncology, Department of Medicine-Lymphoma, Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center
November 6th 2024

Obinutuzumab and Liso-Cel Revisions to CLL/SLL NCCN Guidelines Mark Most Notable Changes of 2024

HD-CAR-1 in Heavily Pretreated CLL | Image Credit: © Dr_Microbe - stock.adobe.com
November 4th 2024

HD-CAR-1 Treatment Is Safe and Feasible in Heavily Pretreated CLL